Arvinas, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation…
FundaMental Pharma, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, announced the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member. Dr. Beher assumes this role from…
Ipsen and Sutro Biopharma announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types…
Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader…
AbbVie and Landos Biopharma announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class,…
Synthekine Inc., an engineered cytokine therapeutics company, today announced a worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. The collaboration will focus on advancing Synthekine’s multiple approaches to optimizing IL-10, with…
GenEdit, a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The companies will employ GenEdit’s NanoGalaxy platform to discover and develop…
Merck, known as MSD outside of the United States and Canada, and Harpoon Therapeutics today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash…
Merck Healthcare today announced a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line…
AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform. The first agreement provides AbbVie an exclusive…